Altimmune, Inc.
Company Stats
- Market Cap
- $556.3M
- as of Sep 30, 2026
- Enterprise Value
- $547.6M
- Shares Outstanding
- 194.5M
- Free Float
- 89.3%
Income Statement
- Revenue
- $41,000
- Operating Income
- -$94.5M
- Net Income
- -$88.1M
- EBITDA
- -$94.4M
Cash Flow
- Free Cash Flow
- -$67.5M
- FCF Yield
- -12.1%
- Owner FCF Yield
- -15.0%
Balance Sheet
- Cash & Equivalents
- $43.8M
- Total Debt
- $35.0M
- Net Cash
- $8.8M
Returns & Capital
- SBC, 3Y Avg
- $13.7M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $41,000 | -$67.5M | -164746.3% |
| FY2024 | $20,000 | — | — |
| FY2023 | $426,000 | -$75.9M | -17806.8% |
| FY2022 | -$68,000 | -$62.7M | — |
| FY2021 | $4.4M | -$90.4M | -2048.7% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 28, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges